JP6353577B2 - 組み合わせ組成物 - Google Patents
組み合わせ組成物 Download PDFInfo
- Publication number
- JP6353577B2 JP6353577B2 JP2017055893A JP2017055893A JP6353577B2 JP 6353577 B2 JP6353577 B2 JP 6353577B2 JP 2017055893 A JP2017055893 A JP 2017055893A JP 2017055893 A JP2017055893 A JP 2017055893A JP 6353577 B2 JP6353577 B2 JP 6353577B2
- Authority
- JP
- Japan
- Prior art keywords
- ibuprofen
- paracetamol
- composition
- combination
- intravenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 34
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 44
- 229960001680 ibuprofen Drugs 0.000 claims description 44
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 40
- 229960005489 paracetamol Drugs 0.000 claims description 40
- 238000001990 intravenous administration Methods 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 230000036407 pain Effects 0.000 claims description 13
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 239000007951 isotonicity adjuster Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- 230000003078 antioxidant effect Effects 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 239000003002 pH adjusting agent Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010024636 Glutathione Proteins 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000001509 sodium citrate Substances 0.000 claims 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 3
- 229960003180 glutathione Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Description
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
を含む。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
a)約125mg乃至約175mgのイブプロフェンと約475mg乃至約525mgのパラセタモールとの組み合わせ;あるいは
b)約275mg乃至約325mgのイブプロフェンと約975mg乃至約1,025mgのパラセタモールとの組み合わせ;
を含む薬剤を、静脈から人に投与することで痛み及び/又は炎症を治療する方法を含む。
a)約150mgのイブプロフェンと約500mgのパラセタモールとの組み合わせ;あるいは
b)約300mgのイブプロフェンと約1,000mgのパラセタモールとの組み合わせ;
を含む。
Claims (15)
- 痛み及び/又は炎症を鎮めるための静脈内組成物であって、該組成物が、人に投与するイブプロフェンとパラセタモールの組み合わせを各投与量あたり:
a)125mg乃至175mgのイブプロフェンと475mg乃至525mgのパラセタモールとの組み合わせ;あるいは
b)275mg乃至325mgのイブプロフェンと975mg乃至1,025mgのパラセタモールとの組み合わせ;
で有することを特徴とする組成物。 - 6時間毎に投与されることを特徴とする、請求項1に記載の静脈内組成物。
- 150mgのイブプロフェンと500mgのパラセタモールとの組み合わせを含むことを特徴とする、請求項1又は2に記載の静脈内組成物。
- 300mgのイブプロフェンと1,000mgのパラセタモールとの組み合わせを含むことを特徴とする、請求項1又は2に記載の静脈内組成物。
- 液剤であることを特徴とする、請求項1、2、3又は4に記載の静脈内組成物。
- 人の痛み及び/又は炎症の治療用静脈内薬剤の製造におけるパラセタモールとイブプロフェンの使用であって、該薬剤が一回の投与量あたり:
a)125mg乃至175mgのイブプロフェンと475mg乃至525mgのパラセタモールとの組み合わせ;あるいは
b)275mg乃至325mgのイブプロフェンと975mg乃至1,025mgのパラセタモールとの組み合わせ;
を含むことを特徴とする使用。 - 該薬剤組成物が6時間毎の投与用であることを特徴とする、請求項6に記載の使用。
- 該薬剤組成物が150mgのイブプロフェンと500mgのパラセタモールとの組み合わせを含むことを特徴とする、請求項6又は7に記載の使用。
- 該薬剤組成物が300mgのイブプロフェンと1,000mgのパラセタモールとの組み合わせを含むことを特徴とする、請求項6又は7に記載の使用。
- 該薬剤組成物が液剤であることを特徴とする、請求項6、7、8又は9に記載の使用。
- 適切な賦形剤を含むことを特徴とする、請求項1乃至4の何れか1項に記載の静脈内組成物。
- 請求項11に記載の静脈内組成物において、前記賦形剤が酸化防止剤、pH調整剤、緩衝剤、等張性作用薬、及び純水の1つまたは複数を含むことを特徴とする静脈内組成物。
- 請求項12に記載の静脈内組成物において、前記酸化防止剤がグルタチオンを含み、前記pH調整剤が水酸化ナトリウム又は塩酸を含み、前記緩衝剤がクエン酸ナトリウムを含み、前記等張性作用薬が塩化ナトリウムを含むことを特徴とする静脈内組成物。
- パラセタモール1,000mg;
イブプロフェン・アルギニン塩553mg;
還元グルタチオン(酸化防止剤として)20mg;
pH5−6にするのに十分な量の水酸化ナトリウム又は塩酸(pH調整剤として);
クエン酸ナトリウム(緩衝剤として)10mg;
等張性を与えるのに十分な量の塩化ナトリウム(等張性作用薬として);及び
組成物を100mlにするのに十分な量の純水を含む
又は
組成物の量が100mlとは異なる場合には上記組成を比例して調整させた他の量を含むことを特徴とする、請求項1に記載の静脈内組成物。 - パラセタモール500mg;
イブプロフェン・アルギニン塩276.5mg;
還元グルタチオン(酸化防止剤として)10mg;
pH5−6にするのに十分な量の水酸化ナトリウム又は塩酸(pH調整剤として);
クエン酸ナトリウム(緩衝剤として)5mg;
等張性を与えるのに十分な量の塩化ナトリウム(等張性作用薬として);及び
組成物を100mlにするのに十分な量の純水を含む
又は
組成物の量が100mlとは異なる場合には上記組成を比例して調整させた他の量を含むことを特徴とする、請求項1に記載の静脈内組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ589011 | 2010-11-04 | ||
NZ58901110 | 2010-11-04 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Division JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017132791A JP2017132791A (ja) | 2017-08-03 |
JP6353577B2 true JP6353577B2 (ja) | 2018-07-04 |
Family
ID=46024668
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Pending JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
JP2017055893A Active JP6353577B2 (ja) | 2010-11-04 | 2017-03-22 | 組み合わせ組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013537631A Pending JP2013541583A (ja) | 2010-11-04 | 2011-10-26 | 組み合わせ組成物 |
Country Status (27)
Country | Link |
---|---|
US (5) | US20130225685A1 (ja) |
EP (1) | EP2635269B1 (ja) |
JP (2) | JP2013541583A (ja) |
KR (1) | KR101900520B1 (ja) |
CN (2) | CN103298464A (ja) |
AU (1) | AU2011324137B2 (ja) |
BR (1) | BR112013010829B8 (ja) |
CA (1) | CA2814057C (ja) |
CL (1) | CL2013001250A1 (ja) |
CO (1) | CO6771406A2 (ja) |
CY (1) | CY1123398T1 (ja) |
DK (1) | DK2635269T3 (ja) |
ES (1) | ES2742373T3 (ja) |
HR (1) | HRP20191489T1 (ja) |
HU (1) | HUE045442T2 (ja) |
LT (1) | LT2635269T (ja) |
MX (2) | MX367209B (ja) |
MY (1) | MY160572A (ja) |
NZ (1) | NZ609727A (ja) |
PH (1) | PH12021550804A1 (ja) |
PL (1) | PL2635269T3 (ja) |
PT (1) | PT2635269T (ja) |
RS (1) | RS59258B1 (ja) |
RU (2) | RU2707089C2 (ja) |
SG (1) | SG189319A1 (ja) |
SI (1) | SI2635269T1 (ja) |
WO (1) | WO2012060719A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ609727A (en) | 2010-11-04 | 2015-07-31 | Aft Pharmaceuticals Ltd | A combination composition comprising ibuprofen and paracetamol |
US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
WO2016008546A1 (en) * | 2014-07-18 | 2016-01-21 | Everbright Pharmaceuticals S.A.R.L. | Aqueous formulation comprising paracetamol and ibuprofen |
CA2963916A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
WO2018192664A1 (en) | 2017-04-20 | 2018-10-25 | Hyloris Developments Sa | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF |
CA3236068A1 (en) * | 2017-07-10 | 2019-01-17 | Gel Cap Technologies, LLC | Dual release dosage form capsule and methods, devices and systems for making same |
US11197830B2 (en) * | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
US11568752B2 (en) * | 2020-01-28 | 2023-01-31 | David Clark Company Incorporated | Gateway retrieval alert device for aircraft pushback operations |
WO2023281089A2 (en) | 2021-07-08 | 2023-01-12 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising naproxen and paracetamol |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997020551A1 (en) * | 1995-12-05 | 1997-06-12 | Adcock Ingram Limited | Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic |
WO2003039532A1 (en) * | 2001-11-02 | 2003-05-15 | Cumberland Pharmaceuticals Inc. | Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid |
BR0318201A (pt) * | 2003-03-21 | 2006-03-21 | Mcneil Ppc Inc | regime de dosagem de fármaco antiinflamatório não-esteroidal |
MX2007000117A (es) * | 2004-07-07 | 2007-06-15 | Aft Pharmaceuticals Ltd | Una composicion de combinacion. |
KR20060072839A (ko) * | 2004-12-23 | 2006-06-28 | 김경태 | 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제 |
US7934627B2 (en) * | 2005-10-13 | 2011-05-03 | Alcoa Inc. | Apparatus and method for high pressure extrusion with molten aluminum |
US8580855B2 (en) * | 2006-10-20 | 2013-11-12 | Mcneil-Ppc, Inc. | Acetaminophen / ibuprofen combinations and method for their use |
WO2008079818A2 (en) * | 2006-12-21 | 2008-07-03 | Soluprin Pharmaceuticals, Inc. | Intravenous administration of water soluble analgesic formulations |
US20090264530A1 (en) * | 2008-04-16 | 2009-10-22 | Nickell Robert P | Combined nsaid and acetaminophen formulation and method |
HUE043063T2 (hu) * | 2008-10-14 | 2019-07-29 | Aft Pharmaceuticals Ltd | Gyógyászati termék és kezelés |
BRPI1006222A2 (pt) * | 2009-03-12 | 2016-08-02 | Cumberland Pharmaceuticas Inc | uso de ibuprofeno na redução de dor em pacientes humanos que são submetidos a cirurgia, uso de ibuprofeno na redução de dor cirúrgica em pacientes humanos e uso de ibuprofeno para melhorar o tempo ambulatorial após a operação em pacientes humanos que sorem procedimentos cirúrgicos ortopédicos |
WO2012005605A1 (en) * | 2010-07-07 | 2012-01-12 | Aft Pharmaceuticals Limited | A combination composition comprising ibuprofen and paracetamol |
NZ609727A (en) | 2010-11-04 | 2015-07-31 | Aft Pharmaceuticals Ltd | A combination composition comprising ibuprofen and paracetamol |
CA2963916A1 (en) * | 2014-10-06 | 2016-04-14 | Cumberland Pharmaceuticals, Inc. | Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain |
-
2011
- 2011-10-26 NZ NZ609727A patent/NZ609727A/en unknown
- 2011-10-26 PL PL11838295T patent/PL2635269T3/pl unknown
- 2011-10-26 US US13/882,953 patent/US20130225685A1/en not_active Abandoned
- 2011-10-26 KR KR1020137014178A patent/KR101900520B1/ko active IP Right Review Request
- 2011-10-26 EP EP11838295.1A patent/EP2635269B1/en active Active
- 2011-10-26 MY MYPI2013001237A patent/MY160572A/en unknown
- 2011-10-26 MX MX2015008709A patent/MX367209B/es unknown
- 2011-10-26 SI SI201131767T patent/SI2635269T1/sl unknown
- 2011-10-26 SG SG2013026265A patent/SG189319A1/en unknown
- 2011-10-26 AU AU2011324137A patent/AU2011324137B2/en active Active
- 2011-10-26 RS RSP20190963 patent/RS59258B1/sr unknown
- 2011-10-26 HU HUE11838295A patent/HUE045442T2/hu unknown
- 2011-10-26 WO PCT/NZ2011/000226 patent/WO2012060719A1/en active Application Filing
- 2011-10-26 ES ES11838295T patent/ES2742373T3/es active Active
- 2011-10-26 RU RU2015103107A patent/RU2707089C2/ru active
- 2011-10-26 CN CN2011800525659A patent/CN103298464A/zh active Pending
- 2011-10-26 RU RU2013123646/15A patent/RU2013123646A/ru not_active Application Discontinuation
- 2011-10-26 LT LTEP11838295.1T patent/LT2635269T/lt unknown
- 2011-10-26 MX MX2013005113A patent/MX2013005113A/es not_active Application Discontinuation
- 2011-10-26 JP JP2013537631A patent/JP2013541583A/ja active Pending
- 2011-10-26 CA CA2814057A patent/CA2814057C/en active Active
- 2011-10-26 PT PT11838295T patent/PT2635269T/pt unknown
- 2011-10-26 BR BR112013010829A patent/BR112013010829B8/pt active IP Right Grant
- 2011-10-26 CN CN201710623266.5A patent/CN107519159A/zh active Pending
- 2011-10-26 DK DK11838295.1T patent/DK2635269T3/da active
-
2013
- 2013-05-06 CL CL2013001250A patent/CL2013001250A1/es unknown
- 2013-05-22 CO CO13125952A patent/CO6771406A2/es not_active Application Discontinuation
-
2015
- 2015-08-21 US US14/832,154 patent/US20160235695A1/en not_active Abandoned
-
2017
- 2017-03-22 JP JP2017055893A patent/JP6353577B2/ja active Active
-
2018
- 2018-10-01 US US16/149,109 patent/US11446266B2/en active Active
-
2019
- 2019-07-18 CY CY20191100766T patent/CY1123398T1/el unknown
- 2019-08-16 HR HRP20191489 patent/HRP20191489T1/hr unknown
-
2021
- 2021-04-08 PH PH12021550804A patent/PH12021550804A1/en unknown
-
2022
- 2022-09-13 US US17/943,708 patent/US11896567B2/en active Active
-
2024
- 2024-01-05 US US18/405,907 patent/US20240207210A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6353577B2 (ja) | 組み合わせ組成物 | |
JP7042531B2 (ja) | デオキシコール酸を含む医薬組成物 | |
KR20160033796A (ko) | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 | |
KR20200055067A (ko) | 성인의 초점성 뇌전증의 치료를 위한 합성 경피성 칸나비디올 | |
JP2005015479A (ja) | 局所麻酔薬を含有する口中用または咽頭部用製剤 | |
AU2011274652B2 (en) | A combination composition comprising ibuprofen and paracetamol | |
EP2515906A2 (en) | Treating critically ill patients with intravenous ibuprofen | |
JP5435659B2 (ja) | トリプタンの経口腔粘膜投与用製剤形態 | |
ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
AU2017305661B2 (en) | New use of N,N-bis-2-mercaptoethyl isophthalamide | |
JP2012525359A (ja) | イブプロフェンリシナートの経口投与用の懸濁液 | |
JP2022540854A (ja) | 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ | |
TW200838534A (en) | Treatment for irritable bowel syndrome | |
JPS5920221A (ja) | レイノ−症状の改善・治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180316 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180522 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6353577 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |